The EUTOS prognostic score: review and validation in 1288
patients with CML treated frontline with imatinib

J 2013

The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib

HOFFMANN, V. S.; M. BACCARANI; D. LINDOERFER; F. CASTAGNETTI; A. TURKINA et al.

Základní údaje

Originální název

The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib

Autoři

HOFFMANN, V. S.; M. BACCARANI; D. LINDOERFER; F. CASTAGNETTI; A. TURKINA; A. ZARITSKY; A. HELLMANN; W. PREJZNER; J.L . STEEGMANN; K. INDRAK; A. COLITA; G. ROSTI; M. PFIRRMANN a Jiří MAYER

Vydání

Leukemia, LONDON, NATURE PUBLISHING GROUP, 2013, 0887-6924

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 9.379

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/13:00070583

Organizační jednotka

Lékařská fakulta

DOI

https://doi.org/10.1038/leu.2013.171

UT WoS

000325642600008

Klíčová slova anglicky

CML; prognosis; tyrosine kinase inhibitors; progression; free survival; cytogenetic remission; EUTOS

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 17. 12. 2013 14:46, Soňa Böhmová

Anotace

V originále

The introduction of tyrosine kinase inhibitors (TKI) in the treatment of Philadelphia chromosome-positive (Ph_) chronic myeloid leukemia (CML) has revolutionized the outcome, but the prognosis of the disease is still based on prognostic systems that were developed in the era of conventional chemotherapy and interferon (IFN)-alfa. A new prognostic score including only two variables, spleen size and basophils, was developed for the prediction of complete cytogenetic response (CCyR) and progression-free survival (PFS). The score was based on a large series of patients who were enrolled in prospective multicenter studies of first-line imatinib treatment. The prognostic value of the EUTOS (European Treatment and Outcome Study for CML) score has now been tested in an independent, multicenter, multinational series of 1288 patients who were treated first-line with imatinib outside prospective studies. It was found that also in these patients, the EUTOS prognostic score was predictive for CCyR, PFS and overall survival (OS). In addition, the prognostic value of the score was reported to be significant in seven of the eight other independent studies of almost 2000 patients that were performed in Europe, the Americas and Asia. The EUTOS risk score is a valid tool for the prediction of the therapeutic effects of TKI, particularly imatinib.

Citovat

HOFFMANN, V. S.; M. BACCARANI; D. LINDOERFER; F. CASTAGNETTI; A. TURKINA; A. ZARITSKY; A. HELLMANN; W. PREJZNER; J.L . STEEGMANN; K. INDRAK; A. COLITA; G. ROSTI; M. PFIRRMANN a Jiří MAYER. The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib. Leukemia. LONDON: NATURE PUBLISHING GROUP, 2013, roč. 27, č. 10, s. 2016-2022. ISSN 0887-6924. Dostupné z: https://doi.org/10.1038/leu.2013.171.

@article{1137366,
   author = {Hoffmann, V. S. and Baccarani, M. and Lindoerfer, D. and Castagnetti, F. and Turkina, A. and Zaritsky, A. and Hellmann, A. and Prejzner, W. and Steegmann, J.L . and Indrak, K. and Colita, A. and Rosti, G. and Pfirrmann, M. and Mayer, Jiří},
   article_location = {LONDON},
   article_number = {10},
   doi = {https://doi.org/10.1038/leu.2013.171},
   keywords = {CML; prognosis; tyrosine kinase inhibitors; progression; free survival; cytogenetic remission; EUTOS},
   language = {eng},
   issn = {0887-6924},
   journal = {Leukemia},
   title = {The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib},
   volume = {27},
   year = {2013}
}

TY  - JOUR
ID  - 1137366
AU  - Hoffmann, V. S. - Baccarani, M. - Lindoerfer, D. - Castagnetti, F. - Turkina, A. - Zaritsky, A. - Hellmann, A. - Prejzner, W. - Steegmann, J.L . - Indrak, K. - Colita, A. - Rosti, G. - Pfirrmann, M. - Mayer, Jiří
PY  - 2013
TI  - The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib
JF  - Leukemia
VL  - 27
IS  - 10
SP  - 2016-2022
EP  - 2016-2022
PB  - NATURE PUBLISHING GROUP
SN  - 08876924
KW  - CML
KW  - prognosis
KW  - tyrosine kinase inhibitors
KW  - progression
KW  - free survival
KW  - cytogenetic remission
KW  - EUTOS
N2  - The introduction of tyrosine kinase inhibitors (TKI) in the treatment of Philadelphia chromosome-positive (Ph_) chronic myeloid leukemia (CML) has revolutionized the outcome, but the prognosis of the disease is still based on prognostic systems that were developed in the era of conventional chemotherapy and interferon (IFN)-alfa. A new prognostic score including only two variables, spleen size and basophils, was developed for the prediction of complete cytogenetic response (CCyR) and progression-free survival (PFS). The score was based on a large series of patients who were enrolled in prospective multicenter studies of first-line imatinib treatment. The prognostic value of the EUTOS (European Treatment and Outcome Study for CML) score has now been tested in an independent, multicenter, multinational series of 1288 patients who were treated first-line with imatinib outside prospective studies. It was found that also in these patients, the EUTOS prognostic score was predictive for CCyR, PFS and overall survival (OS). In addition, the prognostic value of the score was reported to be significant in seven of the eight other independent studies of almost 2000 patients that were performed in Europe, the Americas and Asia. The EUTOS risk score is a valid tool for the prediction of the therapeutic effects of TKI, particularly imatinib.
ER  -

HOFFMANN, V. S.; M. BACCARANI; D. LINDOERFER; F. CASTAGNETTI; A. TURKINA; A. ZARITSKY; A. HELLMANN; W. PREJZNER; J.L . STEEGMANN; K. INDRAK; A. COLITA; G. ROSTI; M. PFIRRMANN a Jiří MAYER. The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib. \textit{Leukemia}. LONDON: NATURE PUBLISHING GROUP, 2013, roč.~27, č.~10, s.~2016-2022. ISSN~0887-6924. Dostupné z: https://doi.org/10.1038/leu.2013.171.

Přehled o publikaci